PAMA CUTS JEOPARDIZE SENIORS' HEALTH AND UNDERMINE PREVENTION EFFORTS



CUTS TO MEDICARE LAB TESTS POSE LONG-TERM HARM TO OVER 59 MILLION SENIORS

HAVE AT LEAST TWO CHRONIC DISEASES

PAMA Cuts Have Already Forced Labs to Reduce Services*

Of labs surveyed by the Infectious Disease Society of America:

Nearly **8 in 10 labs** reported that they would be unable to provide the full range of tests following 2018-2019 cuts

Over 32% of labs have cut back on services offered

Nearly 40% of labs are now referring tests to different labs




Successful disease prevention, monitoring and management require reliable access to routine lab testing.


Public Projections Severely Underestimated Depth Of PAMA Cuts

OMB and CBO projections relied on the assumption that PAMA would be carried out as Congress intended, but because of CMS' flawed implementation, impacts will be much greater than first predicted based on data assumptions pre-COVID-19.


Cuts to Medicare Lab Benefits Over 10 Years




TESTS THAT SENIORS RELY ON THE MOST FACE THE BIGGEST CUTS



Two of the most common lab tests – the Thyroid Hormone Testing and Complete Blood Count (CBC) – face staggering cuts. Every day, seniors rely on these screening tools to identify and manage key health challenges, including:









Cuts To Lab Services Undermine Our Ability To Control Costs Long-term

While lab tests account for less than 3 percent of Medicare Part B spending, they provide critical medical insight that enables early diagnosis and successful disease management. These tests improve patient quality of life and drive meaningful savings for the health system.

SUCCESSFUL DISEASE MANAGEMENT HAS THE POWER TO:



Reduce Hospitalizations by up to **24%**



Cut Medicare costs by 20%



Preventable complications from diabetes cost the U.S.

\$16 Billion in avoidable spending.

Cuts to lab services threaten to exacerbate this problem.

